// App-Quantinova.ai

: A prospective global registry on oral antithrombotic treatment in patients with atrial fibrillation: GLORIA-AF Phase III baseline characteristics

Researchers

Presenter

  • M V Huisman

Principal Investigators

  • H.-C Diener

  • S J Dubner

  • J L Halperin

  • K J Rothman

  • C.-S Ma

  • M Paquette

  • C Teutsch

  • L R Franca

Medical Centers

  • Leiden University Medical Centre, Leiden, Netherlands

  • University Hospital of Essen, Essen, Germany

  • Clinica y Maternidad Suizo Argentina, Buenso Aires, Argentina

  • The Mount Sinai School of Medicine, New York, United States

  • RTI Health Solutions, Durham, NC, United States

  • Beijing Children's Hospital, Beijing, China (People's Republic)

  • Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT, United States.

  • Boehringer Ingelheim Ltd., Ontario, Burlington, Canada

  • Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany,

Locations

  • Netherlands

  • Germany

  • Argentina

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Pradax

Outcome

  • N/A

Study Design

  • Prospective

Phase

  • III

Study Id's

  • N/A

Sponsors

  • Boehringer Ingelheim

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved